Difference between revisions of "Tislelizumab (Baizean)"
Jump to navigation
Jump to search
m (→Also known as) |
m |
||
Line 6: | Line 6: | ||
*[[Esophageal squamous cell carcinoma]] | *[[Esophageal squamous cell carcinoma]] | ||
*[[Nasopharyngeal carcinoma]] | *[[Nasopharyngeal carcinoma]] | ||
− | *[[Non-small cell lung cancer, nonsquamous]] | + | *[[Non-small cell lung cancer]] |
− | *[[Non-small cell lung cancer, squamous]] | + | **[[Non-small cell lung cancer, nonsquamous]] |
+ | **[[Non-small cell lung cancer, squamous]] | ||
==Also known as== | ==Also known as== | ||
Line 18: | Line 19: | ||
[[Category:Esophageal cancer medications]] | [[Category:Esophageal cancer medications]] | ||
[[Category:Nasopharyngeal carcinoma medications]] | [[Category:Nasopharyngeal carcinoma medications]] | ||
+ | [[Category:Non-small cell lung cancer medications]] | ||
[[Category:Non-small cell lung cancer, nonsquamous medications]] | [[Category:Non-small cell lung cancer, nonsquamous medications]] | ||
[[Category:Non-small cell lung cancer, squamous medications]] | [[Category:Non-small cell lung cancer, squamous medications]] | ||
[[Category:NMPA approved drugs]] | [[Category:NMPA approved drugs]] |
Revision as of 11:41, 25 December 2022
Note: Tislelizumab is approved in China for multiple indications, but does not appear to have a brand name at this time.
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, tislelizumab binds to PD-1 and inhibits the binding of PD-1 to the PD-1 ligands programmed cell death-1 ligand 1 (PD-L1), and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T cells and T-cell-mediated immune responses against tumor cells.
Diseases for which it is used
Also known as
- Code name: BGB-A317